2010年1月至今，引用Selleck产品的顶级学术期刊文献已达 431 篇！

已有十四位诺贝尔奖得主使用Selleck产品发表文献45篇！

THE NOBEL PRIZE

THE NOBEL PRIZE

David Julius

2021年获得诺贝尔生理学或医学奖

Michael Houghton

2020年获得诺贝尔生理学或医学奖

Charles M. Rice

2020年获得诺贝尔生理学或医学奖

William G. Kaelin Jr

2019年获得诺贝尔生理学或医学奖

Peter J. Ratcliffe

2019年获得诺贝尔生理学或医学奖

Gregg L. Semenza

2019年获得诺贝尔生理学或医学奖

James P. Allison

2018年获得诺贝尔生理学或医学奖

Michael Rosbash

2017年获得诺贝尔生理学或医学奖

Shinya Yamanaka

2012年获得诺贝尔生理学或医学奖

Eric Richard Kandel

2000年获得诺贝尔生理学或医学奖

Aziz Sancar

2015年获得诺贝尔化学奖

Brian K. Kobilka

2012年获得诺贝尔化学奖

Robert Lefkowitz

2012年获得诺贝尔化学奖

Aaron Ciechanover

2004年获得诺贝尔化学奖

新产品

目录号 产品名 Target Pathway 产品描述
S8944 G150 Others Others G150 is a potent and highly selective human cyclic GMP-AMP synthase (h-cGAS) inhibitor with IC50 of 10.2 nM.
S8913 TH5487 Others Others TH5487 is a selective active-site inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1) with IC50 of 342 nM.
S8938 KGA-2727 SGLT GPCR & G Protein KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models.
S8939 Mizagliflozin SGLT GPCR & G Protein Mizagliflozin is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.
S7013 Guadecitabine (SGI-110) Others Others Guadecitabine (SGI-110) is a next-generation hypomethylating agent whose active metabolite decitabine has a longer in-vivo exposure time than intravenous decitabine.
S8812 CM272 DNA Methyltransferase Epigenetics CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
S9729 Visomitin (SKQ1) Others Others INT-777 (S-EMCA) is a novel potent and selective TGR5 agonist with EC50 values of 0.18 μM, 3.9 μM and 1.45 μM for WT TGR5, TGR5(N76A) and TGR5(Y89F) respectively.
S8500 BAY1125976 Akt PI3K/Akt/mTOR BAY 1125976 is a selective allosteric AKT1/2 inhibitor,exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. BAY1125976 inhibits the activity of AKT1 (IC50 = 5.2 nM at 10 µM ATP and 44 nM at 2 mM ATP) and AKT2 (IC50 = 18 nM at 10 µM ATP and 36 nM at 2 mM ATP) very potently.Whereas BAY1125976 is almost inactive on AKT3 (IC50 = 427 nM at 10 µM ATP).
点击更多